pyrazines has been researched along with azd1656 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Ericsson, H; Hompesch, M; Leonsson-Zachrisson, M; Morrow, LA; Norjavaara, E; Sjöberg, F; Sjöstrand, M | 1 |
| Ericsson, H; Hompesch, M; Knutsson, M; Leonsson-Zachrisson, M; Morrow, LA; Norjavaara, E; Wollbratt, M | 1 |
| Ericsson, H; Heijer, M; Leonsson-Zachrisson, M; Norjavaara, E; Persson, M; Röshammar, D; Ueda, S; Wollbratt, M | 1 |
| Johnsson, E; Leonsson-Zachrisson, M; Wessman, C; Wilding, JP | 1 |
| Hayashi, N; Johnsson, E; Kiyosue, A; Komori, H; Leonsson-Zachrisson, M | 1 |
| Mitchard, T; Stewart, J | 1 |
| Atkinson, AM; Baker, DJ; Charles, AD; Coghlan, M; Jones, HB; Leighton, B; Wilkinson, GP | 1 |
| Hompesch, M; Krentz, AJ; Morrow, L; Norjavaara, E; Petersson, M | 1 |
| Allen, M; Chorlton, J; Hollowood, Z; Lockhart, D; Martin, J; McCafferty, K | 1 |
7 trial(s) available for pyrazines and azd1656
| Article | Year |
|---|---|
Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.
Topics: Adult; Azetidines; Benzamides; Body Mass Index; C-Peptide; Cross-Over Studies; Enzyme Activators; Epinephrine; Glucagon; Glucokinase; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Norepinephrine; Pyrazines; Sulfones; Young Adult | 2012 |
Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
Topics: Adult; Azetidines; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucokinase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Peptide Fragments; Pyrazines; Single-Blind Method; Treatment Outcome | 2012 |
Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.
Topics: Administration, Oral; Adult; Asian People; Azetidines; Biomarkers; Blood Glucose; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Glucokinase; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Models, Biological; Pyrazines; Single-Blind Method; United States; Young Adult | 2012 |
Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin.
Topics: Analysis of Variance; Azetidines; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Enzyme Activation; Enzyme Reactivators; Europe; Fasting; Female; Glucokinase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Time Factors; Treatment Outcome; Triglycerides | 2013 |
Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus.
Topics: Asian People; Azetidines; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fasting; Female; Glucokinase; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Japan; Male; Middle Aged; Pyrazines; Time Factors; Treatment Outcome | 2013 |
Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Topics: Azetidines; Blood Glucose; Body Mass Index; Catecholamines; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Activators; Fasting; Female; Glucagon; Glucokinase; Glucose Clamp Technique; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines | 2014 |
ARCADIA study protocol: a phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with diabetes hospitalised with suspected or confirmed COVID-19.
Topics: Azetidines; Clinical Trials, Phase II as Topic; COVID-19; Diabetes Mellitus, Type 2; Humans; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; State Medicine; Treatment Outcome | 2021 |
2 other study(ies) available for pyrazines and azd1656
| Article | Year |
|---|---|
The novel use of a heterozygous knockout mouse for embryofetal development assessment of a glucokinase activator.
Topics: Animals; Area Under Curve; Azetidines; Dose-Response Relationship, Drug; Embryonic Development; Female; Fetus; Heterozygote; Male; Maternal Exposure; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrazines; Pyridines; Rabbits | 2014 |
Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
Topics: Animals; Azetidines; Biomarkers; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Administration Schedule; Enzyme Activation; Enzyme Activators; Glucokinase; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Knockout; Pyrazines; Rats; Rats, Zucker; Sulfones; Thiadiazoles; Translational Research, Biomedical; Triglycerides | 2014 |